QuidelOrtho to Sell Testing Unit in $1.5B Deal: Report
QuidelOrtho is planning to divest a testing business unit for $1.5 billion, according to the Financial Times.
QuidelOrtho is moving to shed a major business unit in a deal valued at approximately $1.5 billion, the Financial Times reported, marking a significant strategic pivot for the diagnostics company as it looks to streamline operations and sharpen its focus on core assets.
The planned divestiture signals growing pressure on diagnostics firms to restructure portfolios that were significantly reshaped during the COVID-19 pandemic era, when rapid testing demand inflated revenues and prompted a wave of acquisitions. QuidelOrtho itself was formed through the 2022 merger of Quidel Corporation and Ortho Clinical Diagnostics, a combination that left the company managing a broad and complex product lineup.
Read more Bots Are Dominating Ticket Sales — And That's Only Half the Battle →
A $1.5 billion asset sale of this scale would represent a meaningful capital event for QuidelOrtho, potentially providing the company with financial flexibility to pay down debt, return capital to shareholders, or reinvest in higher-growth segments of its diagnostics business. Analysts have long noted that post-merger integration challenges and declining COVID-test demand have weighed on the company's financial performance.
The identity of any potential buyer and the specific testing unit targeted for sale were not detailed in available reporting, leaving key questions about the transaction's scope and strategic rationale still open. Deal timelines and closing conditions also remain unclear at this stage.
Continue reading at SeekingAlpha.
